Bradley Foster & Sargent’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $599K | Sell |
11,427
-65
| -0.6% | -$3.44K | 0.01% | 382 |
|
|
2026
Q1 | $634K | Sell |
11,492
-1,180
| -9% | -$63.9K | 0.01% | 356 |
|
|
2025
Q4 | $621K | Sell |
12,672
-148
| -1% | -$6.9K | 0.01% | 360 |
|
|
2025
Q3 | $553K | Sell |
12,820
-491
| -4% | -$19.2K | 0.01% | 378 |
|
|
2025
Q2 | $511K | Buy |
+13,311
| New | +$509K | 0.01% | 382 |
|
|
2024
Q4 | – | Sell |
-5,322
| Closed | -$218K | – | 471 |
|
|
2024
Q3 | $218K | Sell |
5,322
-252
| -5% | -$10.3K | ﹤0.01% | 447 |
|
|
2024
Q2 | $215K | Buy |
5,574
+81
| +1% | +$3.41K | ﹤0.01% | 433 |
|
|
2024
Q1 | $235K | Sell |
5,493
-185
| -3% | -$7.63K | ﹤0.01% | 417 |
|
|
2023
Q4 | $210K | Sell |
5,678
-165
| -3% | -$5.92K | ﹤0.01% | 421 |
|
|
2023
Q3 | $208K | Hold |
5,843
| – | – | ﹤0.01% | 423 |
|
|
2023
Q2 | $208K | Buy |
5,843
+90
| +2% | +$3.23K | ﹤0.01% | 423 |
|
|
2023
Q1 | $205K | Hold |
5,753
| – | – | ﹤0.01% | 418 |
|
|
2022
Q4 | $202K | Buy |
+5,753
| New | +$192K | 0.01% | 421 |
|
|
2022
Q3 | – | Sell |
-5,714
| Closed | -$311K | – | 429 |
|
|
2022
Q2 | $311K | Sell |
5,714
-379
| -6% | -$20.9K | 0.01% | 378 |
|
|
2022
Q1 | $332K | Buy |
+6,093
| New | +$331K | 0.01% | 398 |
|
|
2020
Q4 | – | Sell |
-6,059
| Closed | -$285K | – | 369 |
|
|
2020
Q3 | $285K | Buy |
+6,059
| New | +$304K | 0.01% | 309 |
|
|
2020
Q1 | $277K | Sell |
5,839
-840
| -13% | -$44.8K | 0.01% | 290 |
|
|
2019
Q4 | $392K | Buy |
6,679
+297
| +5% | +$16.5K | 0.01% | 290 |
|
|
2019
Q3 | $341K | Hold |
6,382
| – | – | 0.01% | 288 |
|
|
2019
Q2 | $319K | Buy |
6,382
+91
| +1% | +$4.57K | 0.01% | 296 |
|
|
2019
Q1 | $329K | Buy |
6,291
+413
| +7% | +$20.6K | 0.01% | 294 |
|
|
2018
Q4 | $281K | Buy |
5,878
+714
| +14% | +$35.2K | 0.01% | 299 |
|
|
2018
Q3 | $259K | Buy |
+5,164
| New | +$262K | 0.01% | 336 |
|
|
2015
Q2 | – | Sell |
-3,962
| Closed | -$229K | – | 352 |
|
|
2015
Q1 | $229K | Hold |
3,962
| – | – | 0.01% | 327 |
|
|
2014
Q4 | $212K | Sell |
3,962
-206
| -5% | -$11.5K | 0.01% | 329 |
|
|
2014
Q3 | $240K | Buy |
4,168
+111
| +3% | +$6.8K | 0.01% | 322 |
|
|
2014
Q2 | $271K | Sell |
4,057
-80
| -2% | -$5.42K | 0.01% | 302 |
|
|
2014
Q1 | $276K | Sell |
4,137
-400
| -9% | -$27K | 0.01% | 298 |
|
|
2013
Q4 | $303K | Sell |
4,537
-313
| -6% | -$20.3K | 0.02% | 294 |
|
|
2013
Q3 | $304K | Buy |
4,850
+1,080
| +29% | +$69.5K | 0.02% | 283 |
|
|
2013
Q2 | $236K | Buy |
+3,770
| New | +$239K | 0.01% | 292 |
|
Other funds holding GSK
JEST
Bradley Foster & Sargent's GSK Position: Q2 2026 in Review
Bradley Foster & Sargent reduced its GSK (GSK) stake by 0.57% in Q2 2026, selling an estimated $3.44K and leaving 11,427 shares worth $599K. The position accounts for 0.01% of the portfolio, ranked #382.
Bradley Foster & Sargent first reported a position in GSK in Q2 2013 and has held it in 31 quarters since. The position peaked at $634K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Bradley Foster & Sargent held 11,427 shares of GSK worth $599K as of Q2 2026.
- Bradley Foster & Sargent sold 65 GSK shares in Q2 2026, an estimated $3.44K.
- GSK made up 0.01% of Bradley Foster & Sargent's portfolio in Q2 2026, its #382 holding.
- Bradley Foster & Sargent first reported a position in GSK in Q2 2013 and has held it in 31 quarters since.
- Bradley Foster & Sargent's GSK position peaked at $634K in Q1 2026.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Bradley Foster & Sargent's 13F filing for Q2 2026, filed 14 Aug 2026.